NAMENDA
LOE ApproachingNDAORALSOLUTION
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
NAMENDA by AbbVie is n-methyl-d-aspartate (nmda) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of alzheimer's disease. Approved for moderate to severe dementia of the alzheimer's type, moderate to severe dementia of the alzheimer's type (). First approved in 2005.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAMENDA (memantine) is an oral solution small-molecule NMDA receptor antagonist approved in 2005 for Alzheimer's disease, though the data indicates indications listed as Hepatocellular Carcinoma and Cirrhosis. It works as a low-to-moderate affinity uncompetitive antagonist that modulates glutamate excitotoxicity, though there is no evidence it prevents or slows neurodegeneration.
$63KPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spend, the brand team is likely in decline mode with reduced commercial headcount and focus on managed care retention rather than growth initiatives.
Mechanism of Action
N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA…
Worked on NAMENDA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.